skip to main content
Idioma:

Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database

Kawasaki, Ryo ; Bauer, Melissa ; Bezlyak, Vladimir ; Ogura, Yuichiro

Japanese journal of ophthalmology, 2021-03, Vol.65 (2), p.215-226 [Periódico revisado por pares]

Tokyo: Springer Japan

Texto completo disponível

Citações Citado por
  • Título:
    Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database
  • Autor: Kawasaki, Ryo ; Bauer, Melissa ; Bezlyak, Vladimir ; Ogura, Yuichiro
  • Assuntos: Age ; Age related diseases ; Clinical Investigation ; Clinical trials ; Computer centers ; Data centers ; Diabetes mellitus ; Diagnosis ; Edema ; Eye diseases ; Growth factors ; Health services ; Macular degeneration ; Medical treatment ; Medicine ; Medicine & Public Health ; Occlusion ; Ophthalmology ; Patients ; Retina ; Vascular endothelial growth factor
  • É parte de: Japanese journal of ophthalmology, 2021-03, Vol.65 (2), p.215-226
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Undefined-1
    ObjectType-Feature-3
    content type line 23
  • Descrição: Purpose To describe treatment patterns in patients diagnosed with neovascular age-related macular degeneration (nAMD), retinal vein occlusion (RVO), or diabetic macular edema (DME), newly-treated with anti-vascular endothelial growth factor (anti-VEGF) agents as recorded in the Japanese Medical Data Center (JMDC) database. Study design This non-interventional, descriptive, retrospective, observational cohort study included insured Japanese patients aged ≥ 21 and ≤ 75 years at index date (anti-VEGF treatment initiation). Methods Patients with minimum one claim in JMDC database with a diagnosis code for nAMD, RVO, or DME between October 2007–May 2015 and with minimum of one claim for anti-VEGF agents on or after the date of diagnosis were included. Frequency and proportion of claims submitted for anti-VEGF injections were assessed during 12 months post-index date. Results The median (interquartile range) number of claims for anti-VEGF injections during 12 months post-index date were 3 (1, 4) for nAMD (n = 255), 2 (1, 3) for RVO (n = 223) and 2 (1, 4) for DME (n = 125) patients. Frequencies of nAMD, RVO and DME patients with one or more claims for a retinal disease treatment other than an anti-VEGF agent were 4 (1.57%), 59 (26.46%) and 68 (54.40%) during the 12 months pre-index date and 21 (8.24%), 85 (38.12%) and 62 (49.60%) in the 12 months post-index date, respectively. Conclusions The median number of anti-VEGF injections per patient was lower than those reported in clinical trials. Although various pre- and concomitant treatments were used in RVO and DME, anti-VEGF monotherapy was the first-line treatment in > 90% of nAMD patients.
  • Editor: Tokyo: Springer Japan
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  5 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.